Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MLYCD | O95822 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25986850 | 0.89 | KMT2A (0.46) | LMNAKMT2AMAOAMAOBMLYCD | |
| SCHEMBL2202823 | 0.81 | KDM4E (0.62) | KDM4ELMNAKMT2ACYP1A2CYP3A4 | |
| SCHEMBL2201636 | 0.76 | ALOX5 (0.55) | KDM4ELMNAKMT2ATDP1MAOB | |
| SCHEMBL2200556 | 0.75 | ALOX5 (0.61) | KDM4ELMNAKMT2AMAOBMLYCD | |
| SCHEMBL2201276 | 0.74 | ALOX5 (0.60) | KDM4EKMT2AMAOBMLYCDNPY5R | |
| SCHEMBL27337424 | 0.71 | TAAR1 (0.53) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL9589232 | 0.71 | TDP1 (0.54) | KDM4ELMNAKMT2ACYP1A2CYP3A4 | |
| SCHEMBL2202453 | 0.71 | KDM4E (0.54) | KDM4ELMNAKMT2AALDH1A1RAB9A | |
| SCHEMBL4064688 | 0.68 | MLYCD (0.67) | KDM4ELMNAKMT2AMLYCDALDH1A1 | |
| SCHEMBL4075667 | 0.68 | KDM4E (0.50) | KDM4ELMNAKMT2ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731946-B2 | Broad spectrum antivirulence, anti-persistence compounds | THE GENERAL HOSPITAL CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731946-B2 | Broad spectrum antivirulence, anti-persistence compounds | ME2, ME1, ME3 | KDM4E 1362/4885LMNA 4037/4885KMT2A 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.